Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via p53 activation. Triglycidyl isocyanurate induces cell apoptosis. Triglycidyl isocyanurate can be used for cancer research.

Product information

CAS Number: 2451-62-9

Molecular Weight: 297.26

Formula: C12H15N3O6

Synonym:

TGIC

Teroxirone

Chemical Name: tris[(oxiran-2-yl)methyl]-1, 3, 5-triazinane-2, 4, 6-trione

Smiles: O=C1N(CC2CO2)C(=O)N(CC2CO2)C(=O)N1CC1CO1

InChiKey: OUPZKGBUJRBPGC-UHFFFAOYSA-N

InChi: InChI=1S/C12H15N3O6/c16-10-13(1-7-4-19-7)11(17)15(3-9-6-21-9)12(18)14(10)2-8-5-20-8/h7-9H,1-6H2

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 50 mg/mL (168.20 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Triglycidyl isocyanurate (0-30 μM; 48 hours) reduces the growth of spheroids of human non-small-cell-lung cancer cells in culture, it leads to a gradual reduction in size for tumorspheres of A549, H460 and H1299 cells. Triglycidyl isocyanurate (0-30 μM; 48 hours) inhibits expression of akt1/2/3 and phosphorylated Aktser473/474/472 of A549, H460 and H1299 tumorspheres, however, the cleavage of PARP and procaspase-3 plus the emergent active caspase-3 fragment are only visible in H460 and A549 tumorspheres.

In Vivo:

Triglycidyl isocyanurate (subcutaneous injection; 1.8 and 3.6 mg/kg; every 2–3 days for total seven times; 30 days) suppresses the growth of xenograft tumors and has no effects on weight in nude mice.

References:

1. Yu-Ling Ni, et al. Teroxirone motivates apoptotic death in tumorspheres of human lung cancer cells. Chem Biol Interact. 2018 Aug 1;291:137-143
2. Seung-Hun Kim, et al. Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells.Biomed Pharmacother. 2018 Mar;99:997-1008

Products are for research use only. Not for human use.